title: Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology.
abstract: Purpose.To improve success of in vitro fertilization (IVF), assisted reproductive technology (ART) experts addressed four questions. What is optimum oocytes number leading to highest live birth rate (LBR)? Are cohort size and embryo quality correlated? Does gonadotropin type affect oocyte yield? Should "freeze-all" policy be adopted in cycles with progesterone >1.5 ng/mL on day of human chorionic gonadotropin (hCG) administration?Methods.Electronic database search included ten studies on which panel gave opinions for improving current practice in controlled ovarian stimulation for ART.Results.Strong association existed between retrieved oocytes number (RON) and LBRs. RON impacted likelihood of ovarian hyperstimulation syndrome (OHSS). Embryo euploidy decreased with age, not with cohort size. Progesterone > 1.5 ng/dL did not impair cycle outcomes in patients with high cohorts and showed disparate results on day of hCG administration.Conclusions.Ovarian stimulation should be designed to retrieve 10-15 oocytes/treatment. Accurate dosage, gonadotropin type, should be selected as per prediction markers of ovarian response. Gonadotropin-releasing hormone (GnRH) antagonist based protocols are advised to avoid OHSS. Cumulative pregnancy rate was most relevant pregnancy endpoint in ART. Cycles with serum progesterone ≥1.5 ng/dL on day of hCG administration should not adopt "freeze-all" policy. Further research is needed due to lack of data availability on progesterone threshold or index.
authors.affiliation: NCARE Group of IVF Centres, Kerala, India.
authors.forename: Baiju
authors.initials: B
authors.lastname: Ahemmed
authors.affiliation: Jananam Fertility Center, Chennai, India.
authors.forename: Vani
authors.initials: V
authors.lastname: Sundarapandian
authors.affiliation: Nova IVI Fertility, Kolkata, India.
authors.forename: Rohit
authors.initials: R
authors.lastname: Gutgutia
authors.affiliation: Cloud 9 Hospitals, Chennai, India.
authors.forename: Sathya
authors.initials: S
authors.lastname: Balasubramanyam
authors.affiliation: Nova IVI Fertility, Mumbai, India.
authors.forename: Richa
authors.initials: R
authors.lastname: Jagtap
authors.affiliation: Cloud 9 Fertility, Bengaluru, India.
authors.forename: Reeta
authors.initials: R
authors.lastname: Biliangady
authors.affiliation: Fertility and IVF-Jaipur Golden Hospital & Gupta Maternity Home, Delhi, India.
authors.forename: Priti
authors.initials: P
authors.lastname: Gupta
authors.affiliation: Gupte Hospital, Pune, India.
authors.forename: Sachin
authors.initials: S
authors.lastname: Jadhav
authors.affiliation: Centre of IVF and Human Reproduction, Sir Ganga Ram Hospital, New Delhi, India.
authors.forename: Ruma
authors.initials: R
authors.lastname: Satwik
authors.affiliation: Medical Affairs, Merck Biopharma, Mumbai, India.
authors.forename: Pavitra Raj
authors.identifier: 0000-0003-0140-9468
authors.initials: PR
authors.lastname: Dewda
authors.affiliation: Medical Affairs, Merck Biopharma, Mumbai, India.
authors.forename: Priti
authors.initials: P
authors.lastname: Thakor
authors.affiliation: ANDROFERT, Andrology and Human Reproduction Clinic, Referral Center for Male Reproduction, Campinas, SP, Brazil.
authors.forename: Sandro C
authors.identifier: 0000-0002-1313-9680
authors.initials: SC
authors.lastname: Esteves